The FDA's Position on Compounded Oral GLP-1s: What Patients Should Know

If you're considering a compounded oral GLP-1, it's worth knowing that the regulatory ground under this entire category has shifted dramatically in the past year — not through one dramatic ban, but through a steady escalation of warning letters, a canceled product launch, and a $132-complaint legal campaign from Novo Nordisk itself. Here's the actual timeline.

The Hims & Hers Case Study: What Happens When a Major Player Tests the Line

The clearest illustration of where the FDA currently draws the line happened in real time in February 2026. Hims & Hers, a large telehealth company, launched a compounded oral semaglutide pill priced at $49/month on February 5. The very next day, the FDA publicly announced it would take "decisive steps" against non-FDA-approved GLP-1 products, and HHS's General Counsel referred the matter to the Department of Justice. Hims & Hers pulled the product from the market on February 7 — two days after launch. By March 9, the company had settled with Novo Nordisk, agreeing to offer the branded Wegovy and Ozempic products instead and to stop marketing compounded GLP-1s altogether.

That's not a company being shut down by a court — it's a company recognizing the regulatory and legal exposure fast enough to reverse course within weeks. It's also a signal about how the FDA and manufacturers are responding to this specific product category in 2026.

The MEDVi Warning Letter

MEDVi, one of the providers we track on this site, received an FDA warning letter on February 20, 2026 (MARCS-CMS #721455) over its marketing practices. We disclose this directly on MEDVi's card wherever it appears on this site. A warning letter is a formal FDA compliance action — it doesn't necessarily mean the medication itself is unsafe, but it does mean the agency identified violations serious enough to put in writing and make public record.

Novo Nordisk's Own Legal Campaign

Separately from FDA enforcement, Novo Nordisk has pursued an aggressive private legal strategy against compounders — 132 federal complaints across 40 states, resulting in 44 permanent injunctions as of recent reporting. Their litigation and product testing have surfaced real quality concerns industry-wide: some tested compounded products contained significant impurity levels, and in at least some cases, products labeled as containing semaglutide contained none at all. This is Novo Nordisk defending its own patents and trademarks, not a neutral regulator — but the underlying quality-control findings are worth knowing regardless of the source.

What This Means If You're Considering a Compounded Oral Product

• The regulatory trend is toward more scrutiny, not less. Three separate enforcement waves (September 2025, March 2026, and ongoing) each expanded the number of companies receiving warning letters.
• A provider's compliance history is public record. The FDA's warning letter database is searchable, and checking it before committing to a provider takes a few minutes.
• Warning letters and product pulls don't always mean the underlying product is dangerous — many citations are about marketing claims (implying FDA approval or equivalence that doesn't exist) rather than the medication's safety. But they do reflect a company's relationship with its regulator, which matters for reliability and continuity of access.
• This is a genuinely fast-moving area. A provider's status can change between when this article was written and when you're reading it — worth a quick independent check before committing.

For the broader legal distinction between compounded and FDA-approved products, see our compounded vs. FDA-approved explainer.